https://www.cnn.com/2023/05/12/health/duchenne-muscular-dystrophy-therapy-fda/index.html
0
0
FDA advisers narrowly vote in favor of experimental gene therapy for rare muscle disease - CNN
5/12/23 at 11:24pm
Organization
CNN
Author
Meg Tirrell
Details
42 words
Summarize
Business & Industrial Health Conditions Science CNN FDA muscle disease SRP-9001
SRP-9001, an experimental gene therapy that aims to slow or stop the progression of Duchenne muscular dystrophy, is being considered for accelerated approval by the FDA.
2 similar articles
Tracking the FDA advisory panel on Sarepta's gene therapy - STAT
FDA adcomm backs accelerated approval of Sarepta's Duchenne gene therapy in close vote - Endpoints News
Create an account or login to join the discussion